Bull Of The Day: Exelixis
Exelixis (EXEL – Free Report) is a $6 billion biotechnology company focused on cancer R&D and the producer of cabozantinib (sold under the brand names Cabometyx and Cometriq), a treatment approved by the FDA for several indications: medullary thyroid cancer, a second line treatment for renal cell carcinoma (RCC), and clinical activity in several other types of metastatic…